Correlation of CpG island methylator phenotype with poor prognosis in hepatocellular carcinoma

被引:26
|
作者
Cheng, Yue [1 ,2 ]
Zhang, Changsong [1 ,3 ]
Zhao, Jun [1 ]
Wang, Chenyang [1 ]
Xu, Yun [1 ]
Han, Zhipeng [1 ]
Jiang, Guocheng [1 ]
Guo, Xianling [1 ]
Li, Rong [1 ]
Bu, Xinxin [1 ]
Wu, Mengchao [1 ]
Wei, Lixin [1 ]
机构
[1] Second Mil Med Univ, Eastern Hepatobiliary Hosp, Tumor Immunol & Gene Therapy Ctr, Shanghai 200438, Peoples R China
[2] Hosp Heyuan City, Dept Clin Oncol, Heyuan City, Guangdong, Peoples R China
[3] Soochow Univ, Coll Med, Changzhou Tumor Hosp, Clin Oncol Lab, Suzhou, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
CIMP; Methylation; Hepatocellular carcinoma; Prognosis; DNA METHYLATION; PROMOTER HYPERMETHYLATION; HEPATIC RESECTION; EPIGENETIC EVENTS; MULTIPLE GENES; TUMOR; EXPRESSION; SURVIVAL; CANCER; LIVER;
D O I
10.1016/j.yexmp.2009.10.008
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
CpG island methylator phenotype (CIMP), in which multiple genes are concurrently methylated, is an important mechanism in hepatocellular carcinoma development. We determined a hypermethylation profile in hepatocellular carcinoma (HCC). We examined the promoter methylation status of 10 genes in 60 cases of hepatocellular carcinoma (HCC), 60 cases of paired non-tumor tissues, and 6 cases of normal tissues by methylation-specific PCR. The average methylated gene numbers were significantly different between HCC and nontumor tissues (p<0.001). We found metastasis, gamma-glutamyl transpeptidase (GGT) and tumor node metastasis (TNM) stage were significantly different among patients with different CIMP status. Patients with high frequency CIMP tumors had significantly worse survival than patients with intermediate frequency or no CIMP tumors (p<0.01 and p<0.05, respectively). Our results suggested that CIMP could serve as a molecular marker of late stage and poorly prognostic HCC development. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:112 / 117
页数:6
相关论文
共 50 条
  • [41] Distinct microbiome in colorectal cancers with the CpG Island Methylator Phenotype
    Sun, Ang
    Cesaroni, Matteo
    Jobin, Christian
    Barrero, Carlos
    Jelinek, Jaroslav
    Sautter, Jacqueline D.
    Rams, Thomas E.
    Merali, Salim
    Issa, Jean-Pierre
    CANCER RESEARCH, 2015, 75
  • [42] CpG island methylator phenotype (CIMP) in cancer: Causes and implications
    Teodoridis, Jens M.
    Hardie, Catriona
    Brown, Robert
    CANCER LETTERS, 2008, 268 (02) : 177 - 186
  • [43] CPG island methylator phenotype in acute myelogenous leukemia.
    Toyota, M
    Kopecky, KJ
    Ohe-Toyota, M
    Willman, CL
    Issa, JPJ
    BLOOD, 1999, 94 (10) : 491A - 491A
  • [45] CpG Island Methylator Phenotype in Colorectal Cancer: A Current Perspective
    Goel, Ajay
    Shin, Sung Kwan
    CURRENT COLORECTAL CANCER REPORTS, 2008, 4 (02) : 77 - 83
  • [46] Advances in CpG Island Methylator Phenotype Colorectal Cancer Therapies
    Zhang, Xiaofei
    Zhang, Wenjun
    Cao, Pingan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] The CpG island methylator phenotype in colorectal cancer: Progress and problems
    Hughes, Laura A. E.
    Khalid-de Bakker, Carolina A. J.
    Smits, Kim M.
    van den Brandt, Piet A.
    Jonkers, Daisy
    Ahuja, Nita
    Herman, James G.
    Weijenberg, Matty P.
    van Engeland, Manon
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2012, 1825 (01): : 77 - 85
  • [48] Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype
    Bae, Jeong Mo
    Kim, Jung Ho
    Kang, Gyeong Hoon
    HISTOLOGY AND HISTOPATHOLOGY, 2013, 28 (05) : 585 - 595
  • [49] Status and Significance of CpG Island Methylator Phenotype in Endometrial Cancer
    Zhang, Qing-Ying
    Yi, De-Qing
    Zhou, Li
    Zhang, Dong-Hong
    Zhou, Tai-Mei
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2011, 72 (03) : 183 - 191
  • [50] The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status
    Dahlin, Anna M.
    Palmqvist, Richard
    Henriksson, Maria L.
    Jacobsson, Maria
    Eklof, Vincy
    Rutegard, Jorgen
    Oberg, Ake
    Van Guelpen, Bethany R.
    CLINICAL CANCER RESEARCH, 2010, 16 (06) : 1845 - 1855